7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Inflammation-induced brain endothelial activation leads to uptake of electrostatically stabilized iron oxide nanoparticles via sulfated glycosaminoglycans.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Based on our previous data on the presence of very small superparamagnetic iron oxide nanoparticles (VSOP) on brain endothelial structures during experimental autoimmune encephalomyelitis (EAE), we investigated the mechanisms of VSOP binding on inflamed brain endothelial cells in vivo and in vitro. After intravenous application, VSOP were detected in brain endothelial cells of EAE animals at peak disease and prior to clinical onset. In vitro, inflammatory stimuli increased VSOP uptake by brain endothelial bEnd.3 cells, which we confirmed in primary endothelial cells and in bEnd.3 cells cultured under shear stress. Transmission electron microscopy and blocking experiments revealed that during inflammation VSOP were endocytosed by bEnd.3. Modified sulfated glycosaminoglycans (GAG) on inflamed brain endothelial cells were the primary binding site for VSOP, as GAG degradation and inhibition of GAG sulfation reduced VSOP uptake. Thus, VSOP-based MRI is sensitive to visualize early neuroinflammatory processes such as GAG modifications on brain endothelial cells.

          Related collections

          Author and article information

          Journal
          Nanomedicine
          Nanomedicine : nanotechnology, biology, and medicine
          Elsevier BV
          1549-9642
          1549-9634
          Jan 25 2017
          Affiliations
          [1 ] Institute for Medical Immunology, Charité-Universtitätsmedizin Berlin, Berlin, Germany; Cluster of Excellence NeuroCure and Department of Neurology and Experimental and Clinical Research Center, Universitätsmedizin Berlin, Berlin, Germany.
          [2 ] Institute for Medical Immunology, Charité-Universtitätsmedizin Berlin, Berlin, Germany; Experimental and clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité Universitätsmedizin, Berlin.
          [3 ] Department of Radiology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
          [4 ] Medizinische Klinik mit Schwerpunkt Kardiologie und Angiologie, Charité, Universitätsmedizin Berlin, Berlin, Germany.
          [5 ] Experimental and clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité Universitätsmedizin, Berlin; Cluster of Excellence NeuroCure and Department of Neurology and Experimental and Clinical Research Center, Universitätsmedizin Berlin, Berlin, Germany.
          [6 ] Cluster of Excellence NeuroCure and Department of Neurology and Experimental and Clinical Research Center, Universitätsmedizin Berlin, Berlin, Germany.
          [7 ] Institute for Medical Immunology, Charité-Universtitätsmedizin Berlin, Berlin, Germany; Experimental and clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité Universitätsmedizin, Berlin. Electronic address: carmen.infante@charite.de.
          Article
          S1549-9634(17)30012-6
          10.1016/j.nano.2017.01.010
          28131884
          a4b357ce-69c1-4f18-95c3-2e009b52bca0
          History

          Brain endothelial cells,Extracellular matrix,Glycosaminglycans,Nanoparticles,Neuroinflammation,VSOP

          Comments

          Comment on this article